Key facts
- Notable investors include NLC Health Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Revadix
- ·The full record, as it builds
Funding rounds
No funding rounds for Revadix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Revadix
Developer of small molecule therapies designed for the treatment of atrial fibrillation and related heart rhythm disorders. The company focuses on targeting a specific cellular signaling protein through its lead compound that has shown high selectivity and effectiveness in laboratory and patient-derived heart cell studies, enabling the cardiovascular healthcare market to access new, non-invasive approaches to managing irregular heart rhythms.
- Sector
- Healthcare
- HQ
- Toulouse, France
- Founded
- 2025
- Website
- revadix.com/
- Ownership
- Privately Held (backing)
Revadix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Revadix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Revadix in its N-PORT filings yet. We sweep new filings monthly.